Skip to main content
Erschienen in: Journal of General Internal Medicine 7/2021

14.04.2021 | Clinical Vignette

Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature

verfasst von: Mrudula Thiriveedi, MD, Taylor D. Steuber, PharmD, Mohamed Hasan, MD, Alan Baggett, MD, FACP

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Excerpt

A 49-year-old woman presented with a 1-day history of sharp left-sided pleuritic chest pain radiating to the back and associated with shortness of breath. Her past medical history was significant for fistulizing Crohn’s disease (CD) diagnosed in 2011, status post hemicolectomy. She was on prednisone intermittently over the first few years after diagnosis and reportedly had never been on aminosalicylates (mesalamine or sulfasalazine), thiopurines such as azathioprine or 6-mercaptopurine, or methotrexate. At the time of presentation, she was not taking prednisone or any other corticosteroids. She was started on infliximab therapy a year prior to admission and had initially received infusions every 8 weeks prior to switching to every 6 weeks. Additionally, she had missed her most recent dose that was due 3 weeks prior due to insurance issues, so it had been 9 weeks since her last dose. She denied any preceding viral prodromal symptoms including fever, chills, myalgia, headache, cough, rhinitis, nausea, or vomiting and also denied any previous sick contacts or recent travel. …
Literatur
1.
Zurück zum Zitat Lichtenstein GR, Loftus Jr EV, Isaacs KI, Regeuiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113:481-517.CrossRef Lichtenstein GR, Loftus Jr EV, Isaacs KI, Regeuiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113:481-517.CrossRef
2.
Zurück zum Zitat Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46 (8):645-660.CrossRef Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46 (8):645-660.CrossRef
3.
Zurück zum Zitat Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018;19 (8):2244.CrossRef Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018;19 (8):2244.CrossRef
4.
Zurück zum Zitat Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor- Induced Systemic Lupus Erythematosus. Open Rheumatol J 2012;6:315-319.CrossRef Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor- Induced Systemic Lupus Erythematosus. Open Rheumatol J 2012;6:315-319.CrossRef
5.
Zurück zum Zitat Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9: 188–193.CrossRef Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9: 188–193.CrossRef
6.
Zurück zum Zitat Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O’Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn’s disease. Inflamm Bowel Dis 2008;14 (3):428–429.CrossRef Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O’Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn’s disease. Inflamm Bowel Dis 2008;14 (3):428–429.CrossRef
7.
Zurück zum Zitat Perez-De-Lis M, Retamozo S, Florez-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017;16 (11):1255-1271.CrossRef Perez-De-Lis M, Retamozo S, Florez-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017;16 (11):1255-1271.CrossRef
8.
Zurück zum Zitat Pereira VM, Andrade C, Figueira R, Faria G, Jasmins L. Infliximab-induced lupus: a case report. GE-Portuguese Journal of Gastroenterology 2017;24 (2):84–88.CrossRef Pereira VM, Andrade C, Figueira R, Faria G, Jasmins L. Infliximab-induced lupus: a case report. GE-Portuguese Journal of Gastroenterology 2017;24 (2):84–88.CrossRef
9.
Zurück zum Zitat Mizra M, Mizra M, Murugesan V, Olano A. Pericardial effusion due to infliximab therapy for ulcerative colitis. Case Rep Gastrointest Med 2018; Article 4324592. Mizra M, Mizra M, Murugesan V, Olano A. Pericardial effusion due to infliximab therapy for ulcerative colitis. Case Rep Gastrointest Med 2018; Article 4324592.
10.
Zurück zum Zitat Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86:242-251.CrossRef Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86:242-251.CrossRef
11.
Zurück zum Zitat Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis alpha agents. Semin Arthritis Rheum 2008;37 (6):381-387.CrossRef Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis alpha agents. Semin Arthritis Rheum 2008;37 (6):381-387.CrossRef
12.
Zurück zum Zitat Saddler K, Castro-Lainez MT, Deliz-Aguirre R, et al. Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy. IDCases 2019; 15: e00500.CrossRef Saddler K, Castro-Lainez MT, Deliz-Aguirre R, et al. Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy. IDCases 2019; 15: e00500.CrossRef
13.
Zurück zum Zitat Naseer M, Kulairi Z, Kam M. Cardiac tamponade as a presenting manifestation of infliximab-induced lupus in patient treated for Crohn’s disease. ACG Case Rep 2017;4:e1.CrossRef Naseer M, Kulairi Z, Kam M. Cardiac tamponade as a presenting manifestation of infliximab-induced lupus in patient treated for Crohn’s disease. ACG Case Rep 2017;4:e1.CrossRef
14.
Zurück zum Zitat Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther 2018;43(1):107-109.CrossRef Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther 2018;43(1):107-109.CrossRef
15.
Zurück zum Zitat Lather HD, Henry D, Kahlenberg JM. Hemorrhagic pericardial effusion with tamponade: a rare adverse effect of infliximab-case report and literature review. Case Reports in Rheumatology 2016; Article: 2576496. Lather HD, Henry D, Kahlenberg JM. Hemorrhagic pericardial effusion with tamponade: a rare adverse effect of infliximab-case report and literature review. Case Reports in Rheumatology 2016; Article: 2576496.
16.
Zurück zum Zitat Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol 2014; 30 (2):247.e11-2.CrossRef Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol 2014; 30 (2):247.e11-2.CrossRef
17.
Zurück zum Zitat Nakamura Y, Izumi C, Nakagawa Y, Hatta K. A case of effusive–constrictive pericarditis accompanying rheumatoid arthritis: The possibility of adverse effect of TNF-inhibitor therapy J Cardiol Cases 2013;7 (1):e8-e10.CrossRef Nakamura Y, Izumi C, Nakagawa Y, Hatta K. A case of effusive–constrictive pericarditis accompanying rheumatoid arthritis: The possibility of adverse effect of TNF-inhibitor therapy J Cardiol Cases 2013;7 (1):e8-e10.CrossRef
18.
Zurück zum Zitat Devasahayam J, Pillai U, Lacasse A. A rare case of pericarditis, complication of infliximab treatment for Crohn’s disease. Journal of Crohn’s and Colitis 2012;6(6):730-731.CrossRef Devasahayam J, Pillai U, Lacasse A. A rare case of pericarditis, complication of infliximab treatment for Crohn’s disease. Journal of Crohn’s and Colitis 2012;6(6):730-731.CrossRef
19.
Zurück zum Zitat Harney S, O’Shea FD, Fitzgerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis. Ann Rheum Dis 2002;61:653-654.CrossRef Harney S, O’Shea FD, Fitzgerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis. Ann Rheum Dis 2002;61:653-654.CrossRef
20.
Zurück zum Zitat Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis. Therapy Adv Gastroenterol 2016;9(3):330–338.CrossRef Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis. Therapy Adv Gastroenterol 2016;9(3):330–338.CrossRef
21.
Zurück zum Zitat Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66 (5):839-851.CrossRef Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66 (5):839-851.CrossRef
Metadaten
Titel
Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature
verfasst von
Mrudula Thiriveedi, MD
Taylor D. Steuber, PharmD
Mohamed Hasan, MD
Alan Baggett, MD, FACP
Publikationsdatum
14.04.2021
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 7/2021
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06781-x

Weitere Artikel der Ausgabe 7/2021

Journal of General Internal Medicine 7/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.